Patents by Inventor Jonathan Rios-Doria

Jonathan Rios-Doria has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10287362
    Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: May 14, 2019
    Assignee: MedImmune Limited
    Inventors: Carl Hay, Kris Sachsenmeier, Erin Sult, Qihui Huang, Peter Pavlik, Melissa Damschroder, Li Cheng, Gundo Diedrich, Jonathan Rios-Doria, Scott Hammond, Ralph Minter, Steve Rust, Sandrine Guillard, Robert Hollingsworth, Lutz Jermutus, Nicholas Durham, Ching Ching Leow, Mary Antonysamy, James Geoghegan, Xiaojun Lu, Kim Rosenthal
  • Publication number: 20190076452
    Abstract: The invention features doxorubicin or Doxil in combination with a checkpoint inhibitor (e.g., an anti-CTLA-4 antibody, anti-PD-1 antibody, an anti-PD-L1 antibody, GITR ligand, or OX40 fusion protein (FP) and methods of using the combination to enhance anti-tumor activity in a subject.
    Type: Application
    Filed: November 10, 2015
    Publication date: March 14, 2019
    Inventors: Jonathan RIOS-DORIA, ROBERT E. HOLLINGSWORTH
  • Publication number: 20180194858
    Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.
    Type: Application
    Filed: February 23, 2018
    Publication date: July 12, 2018
    Inventors: Carl HAY, Kris SACHSENMEIER, Erin SULT, Qihui Huang, Peter PAVLIK, Melissa DAMSCHRODER, Li CHENG, Gundo DIEDRICH, Jonathan RIOS-DORIA, Scott HAMMOND, Ralph MINTER, Steve RUST, Sandrine GUILLARD, Robert HOLLINGSWORTH, Lutz JERMUTUS, Nicholas DURHAM, Ching Ching LEOW, Mary ANTONYSAMY, James GEOGHEGAN, Xiaojun LU, Kim ROSENTHAL
  • Patent number: 9938356
    Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: April 10, 2018
    Assignee: MEDIMMUNE LIMITED
    Inventors: Carl Hay, Kris Sachsenmeier, Erin Sult, Qihui Huang, Peter Pavlik, Melissa Damschroder, Li Cheng, Gundo Diedrich, Jonathan Rios-Doria, Scott Hammond, Ralph Minter, Steve Rust, Sandrine Guillard, Robert Hollingsworth, Lutz Jermutus, Nicholas Durham, Ching Ching Leow, Mary Antonysamy, James Geoghegan, Xiaojun Lu, Kim Rosenthal
  • Publication number: 20160194407
    Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.
    Type: Application
    Filed: November 9, 2015
    Publication date: July 7, 2016
    Inventors: Carl HAY, Kris Sachsenmeier, Erin Sult, Qihui Huang, Peter Pavlik, Melissa Damschroder, Li Cheng, Gundo Diedrich, Jonathan Rios-Doria, Scott Hammond, Ralph Minter, Steve Rust, Sandrine Guillard, Robert Hollingsworth, Lutz Jermutus, Nicholas Durham, Ching Ching Leow, Mary Antonysamy, James Geoghegan, Xiaojun Lu, Kim Rosenthal
  • Publication number: 20130309277
    Abstract: The present invention provides micelles having an anthracycline encapsulated therein, the micelles comprising a multiblock copolymer. The invention further provides methods of preparing and using said micelles, and compositions thereof.
    Type: Application
    Filed: July 25, 2013
    Publication date: November 21, 2013
    Applicant: Intezyne Technologies, Incorporated
    Inventors: Kevin N. Sill, Habib Skaff, Jonathan Rios-Doria
  • Patent number: 8524783
    Abstract: The present invention provides micelles having an anthracycline encapsulated therein, the micelles comprising a multiblock copolymer. The invention further provides methods of preparing and using said micelles, and compositions thereof.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: September 3, 2013
    Assignee: Intezyne Technologies, Incorporated
    Inventors: Kevin N. Sill, Habib Skaff, Jonathan Rios-Doria, Gregoire Cardoen
  • Patent number: 8524784
    Abstract: The present invention provides micelles having an anthracycline encapsulated therein, the micelles comprising a multiblock copolymer. The invention further provides methods of preparing and using said micelles, and compositions thereof.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: September 3, 2013
    Assignee: Intezyne Technologies, Incorporated
    Inventors: Kevin N. Sill, Habib Skaff, Jonathan Rios-Doria
  • Publication number: 20110142950
    Abstract: The present invention provides micelles having an anthracycline encapsulated therein, the micelles comprising a multiblock copolymer. The invention further provides methods of preparing and using said micelles, and compositions thereof.
    Type: Application
    Filed: October 29, 2010
    Publication date: June 16, 2011
    Applicant: INTEZYNE TECHNOLOGIES, INCORPORATED
    Inventors: Kevin N. Sill, Habib Skaff, Jonathan Rios-Doria
  • Publication number: 20100278928
    Abstract: The present invention provides micelles having an anthracycline encapsulated therein, the micelles comprising a multiblock copolymer. The invention further provides methods of preparing and using said micelles, and compositions thereof.
    Type: Application
    Filed: April 30, 2010
    Publication date: November 4, 2010
    Applicant: Intezyne Technologies, Incorporated
    Inventors: Kevin N. Sill, Jonathan Rios-Doria, Habib Skaff, Gregoire Cardoen
  • Publication number: 20100278932
    Abstract: The present invention provides micelles having SN-38 encapsulated therein.
    Type: Application
    Filed: May 4, 2010
    Publication date: November 4, 2010
    Applicant: Intezyne Technologies, Incorporated
    Inventors: Kevin N. Sill, Habib Skaff, Adam Carie, Jonathan Rios-Doria, Richard Slama, Gregoire Cardoen
  • Publication number: 20090110662
    Abstract: The present invention relates to the field of polymer chemistry and more particularly to click-functionalized targeting compounds and methods for using the same.
    Type: Application
    Filed: April 30, 2008
    Publication date: April 30, 2009
    Applicant: Intezyne Technologies, Inc.
    Inventors: Kurt Breitenkamp, Jonathan Rios-Doria, Rebecca Breitenkamp, Kevin N. Sill, Habib Skaff